Immunohistochemical characterization of γ-secretase activating protein expression in Alzheimer's disease brains

Neuropathology and Applied Neurobiology

Volumn 38, Issue 2, 2012, Pages 132-141

  Satoh, J ^a   Tabunoki, H ^a   Ishida, T ^b   Saito, Y ^c   Arima, K ^c  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b National Center for Global Health and Medicine   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Alzheimer's disease; Amyloid ; GSAP; Immunohistochemistry; PION

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE; GAMMA SECRETASE ACTIVATING PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEURONS; PLAQUE, AMYLOID; PRESENILIN-1; PROTEINS;

EID: 84857808095     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01206.x     Document Type: Article

References (12)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66
2. De Strooper B, Annaert W. Novel research horizons for presenilins and γ-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010; 26: 235-60
3. Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer's disease. Neurotherapeutics 2008; 5: 391-8
4. Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P. Gleevec inhibits β-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 2003; 100: 12444-9
5. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP, Greengard P. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010; 467: 95-8
6. St George-Hyslop P, Schmitt-Ulms G. Alzheimer's disease: selectively tuning γ-secretase. Nature 2010; 467: 36-7
7. Mirra SS, Gearing M, McKeel DW Jr, Crain BJ, Hughes JP, van Belle G, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86
8. Misawa T, Arima K, Mizusawa H, Satoh J. Close association of water channel AQP1 with amyloid-β deposition in Alzheimer disease brains. Acta Neuropathol 2008; 116: 247-60
9. Satoh J, Tabunoki H, Arima K. Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. Dis Markers 2009; 27: 239-52
10. Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T, Satoh J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 2010; 36: 320-30
11. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59
12. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404